Physician profile
Jay K Berkowitz
NPI 1255382396
$14,374.34
in general payments reported to CMS, 2019-2025
27 companies · $3,082 in 2025
The $3,082 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.44 · 2020: $375 · 2021: $2,152 · 2022: $1,912 · 2023: $2,860 · 2024: $3,963 · 2025: $3,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,905.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,159.54 | 2021-2025 | Vraylar |
| Corium, LLC | $3,906.23 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,240.99 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $513.80 | 2020-2025 | Trintellix |
| Alkermes, INC. | $508.51 | 2022-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $488.07 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $443.02 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $396.67 | 2021-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $336.21 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $293.51 | 2020-2025 | Rexulti |
| Almatica Pharma LLC | $284.16 | 2023-2025 | Loreev Xr |
| Axsome Therapeutics, INC. | $272.81 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $259.27 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $204.17 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $178.25 | 2023-2024 | Jornay Pm |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $137.11 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $133.40 | 2021-2025 | Fanapt |
| Allergan, INC. | $131.83 | 2020 | |
| Avanir Pharmaceuticals, INC. | $108.35 | 2021 | |
| Eisai INC. | $67.38 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $64.92 | 2024-2025 | Quviviq, Quviviq |
| Tempus Ai, INC | $61.63 | 2024 | |
| Tris Pharma INC | $49.59 | 2024-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $44.58 | 2021-2025 | Spravato |
| Merck Sharp & Dohme LLC | $41.66 | 2022 | |
| Vertical Pharmaceuticals, LLC | $33.27 | 2024 | Relexxii |
| Indivior INC. | $15.41 | 2025 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Berkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.